Archives — March 2017 back to current month (50)
The release of the bankable feasibility study for the JV Montagne d'Or gold project in French Guiana, with Columbus Gold in partnership with Nordgold, has experts speculating on buyout prospects.
Millennial Lithium, which closed a private placement of nearly $6 million and is resuming drilling at Pastos Grandes in Argentina, has set its sights on producing lithium within three years as lithium demand is projected to skyrocket.
With a swab taken from the inside of a patient's cheek, 3D Signatures' TeloView platform has demonstrated its ability to diagnose Alzheimer's disease, and also to assess whether the disease is manifesting in a mild, moderate or severe form.
Recent drilling at Southern Silver's flagship Cerro Las Minitas project in Mexico shows higher grade silver than previous drilling.
Hold On to These Yields of 8% to Over 9% (03/28/2017)
Money manager Adrian Day reviews the business development companies in his portfolio that are held for income.
Precious Metals Are in Alignment for a Major Ascent (03/27/2017)
Precious metals expert Michael Ballanger discusses silver's recent price performance and why he believes precious metals are in alignment for a major ascent.
Jack Chan’s Weekly Gold and Silver Update (03/25/2017)
Technical analyst Jack Chan charts the latest moves in the gold and silver markets, noting a tug-of-war between support and resistance.
Collapsing oil prices are only the beginning as fossil fuels are turning into a historic relic, says Kenneth Ameduri, chief editor of Crush the Street. He discusses two commodities whose demand he expects to skyrocket as the world shifts to cleaner energy.
Ray Dalio's Hottest Investment Theme Today (03/24/2017)
Since March 15, when the Federal Reserve raised rates for the second time since Trump was elected, gold has rallied and stock outflows have been extremely high, says Tom Beck, senior editor of Portfolio Wealth Global, and he discusses how Ray Dalio is turning to precious metals and industrial commodities right now.
A Credit Implosion Is Coming (03/24/2017)
The biggest bubble of all is bursting—the bond market, where companies and the government borrow money—and it's twice as big as the stock market, says Lior Gantz of Wealth Research Group.
Analysts watching the uranium market agree that as prices for U3O8 turn around, Energy Fuels' U.S.-based assets, including its conventional and in-situ recovery operations at the Canyon Mine and Nichols Ranch, respectively, make it a good bet for investors. The company's management team and directors must agree because they have upped their share ownership.
Dataram's plans to acquire U.S. Gold Corp. to diversify its business would give it access to potentially high-growth mining projects in Nevada and Wyoming.
NexGen's latest mineral resource estimate for the Rook I property has caught the attention of industry analysts.
Iskut Could Be as Important to Seabridge as KSM (03/23/2017)
Seabridge's Iskut project has the potential to be another success story like its flagship, 100%-owned KSM project.
Juniors to Recover as Gold Moves Ahead (03/23/2017)
Fund manager Adrian Day discusses several mining and energy companies in his portfolio that he believes should appreciate now that the recently released Canadian budget does not include a tax rate increase.
Buy Gold Stocks Patiently (03/22/2017)
Money manager Adrian Day discusses three stocks in his portfolio that he sees as buys.
Columbus Discovered a Gold Mine (03/22/2017)
Bob Moriarty of 321 Gold looks at the bankable feasibility study that just came out on Columbus Gold's Montagne d'Or gold project in French Guiana and concludes that it's going to be a mine.
A Core Holding Keeps Getting Better (03/21/2017)
Fund manager Adrian Day reviews one of his favorite resource companies and updates a few others.
Therapix Biosciences launches its IPO on NASDAQ on Wednesday, March 22, under the trading symbol TRPX. The Tel Aviv-based company specializing in the development and commercialization of cannabinoid-based treatments has a drug for Tourette Syndrome in Phase 2a trials and is additionally developing a drug for mild cognitive impairment. The IPO helps put it on a path to join much larger companies developing cannabinoid-based drugs.
Warren Buffett's Biggest Loss (03/20/2017)
Tom Beck of Portfolio Wealth Global shares his strategy for investing in commodities.
Gold for Protection; This Metal for Wealth (03/19/2017)
Inflation has been rising at a rapid rate since the election. Not only is the CPI up, but the Dow Jones just experienced its fastest 1,000-point move in history. With the bull market in its ninth year, Lior Gantz of Wealth Research Group believes this is the time for investors to become very selective, and he points to one commodity that is experiencing very tight supply right now.
Jack Chan's Weekly Gold and Silver Update (03/18/2017)
Technical analyst Jack Chan charts the latest moves in the gold and silver sectors.
Gold Stocks for All Risk Appetites (03/16/2017)
Money manager Adrian Day reviews recent developments at a handful of gold companies, both juniors and seniors.
Canaccord Genuity has released the second edition of its Sustainability and Special Situations Watch List, featuring five companies in the sustainability sector.
Silver Wheaton and Franco-Nevada hosted a mine tour of the Antamina Mine in Peru on March 2, and the promise of substantial additions to the streaming company's assets prompted positive comments from two industry analysts.
High-impact drilling on Pan Orient Energy's East Jabung project in Sumatra, Indonesia, is slated to begin by the end of March.
Trevali Proving Zinc Is Golden (03/16/2017)
Trevali Mining has added a portfolio of zinc assets to its already impressive resource list with the purchase of Glencore's producing Rosh Pinah and Perkoa zinc mines.
RepliCel's successful conclusion of its Phase 1 trial for hair loss sets it up for the next steps in the drug's development.
Time to Get Back into Gold Stocks (03/13/2017)
Money manager Adrian Day updates developments and guidance from three major gold companies.
Technical analyst Jack Chan sets forth data that signals the potential return of a bear market in the precious metals.
Integra Gold's updated 2017 PEA on the Lamaque South Gold Project doubled the life of mine estimate, increased total ounces 156% and reduced total mine costs to CA$86/tonne.
Gold Standard Ventures' aggressive 2017 drill program has the potential to substantially increase resources at its Nevada project, and with Goldcorp and OceanaGold owning substantial percentages of the company, Gold Standard has already caught the eye of producers.
Several zinc mines have shut down in the past few years due to depletion, and the warehouse inventory levels of the base metal have been steadily declining. The market is finally waking up and starting to look at zinc companies again. Thibaut Lepouttre of Caesars Report profiles Darnley Bay Resources, one of the companies hoping to fill the supply gap.
3D Signatures continues to advance its cutting-edge technology for prostate cancer liquid biopsies and Hodgkin's lymphoma tests.
Precious metals expert Michael Ballanger reflects on the cause of this week's decline in precious metals markets, and contemplates the factors that will help him determine a bottom.
Investors Are Becoming Bullish on Commodities (03/07/2017)
Investors are increasingly turning to commodities as prices rally.
The 'Trump Trade' Is Too Optimistic (03/06/2017)
Tom Beck of Portfolio Wealth Global believes the "Trump Trade" is overblown and recommends investors bulletproof their holdings.
Citing the uncertainty caused by China dumping U.S. Treasuries, an impending debt ceiling crisis, the upcoming French elections, and more, Wealth Research Group editor Lior Gantz advises investors to make sure their portfolios are diversified.
The Barron Is Back (03/06/2017)
Bob Moriarty of 321 Gold chronicles the career of Dr. Keith Barron and his latest foray in Ecuador.
Technical analyst Jack Chan finds the latest Commitment of Traders (COT) data alarming and explains what the COT charts predict for the gold and silver markets.
Looking at the charts, technical analyst Clive Maund sees copper "riding for a fall."
Technical analyst Clive Maund charts changes that portend a "brutal decline" in both the oil and precious metals markets.
The Precious Metals Sector 'Tips Its Hand' (03/03/2017)
It is common for commodities to drop in unison, says technical analyst Clive Maund, and in tandem with his prediction that oil will drop, he also sees gold and silver going lower.
Inflation, the Dollar and Gold (03/03/2017)
Rudi Fronk and Jim Anthony, co-founders of Seabridge Gold, discuss anticipated interest rate action by the Fed and its possible effect on gold.
Broadway Gold Ramps Up Exploration at Madison Mine (03/02/2017)
Broadway Gold Mining has recently begun both surface and underground mining at its Madison Mine, advancing exploration at the historic gold-copper project in the Butte-Anaconda mining district of Montana and netting the attention of industry watchers.
Hafnium may not be a household word, but demand for the element is growing, and Alkane Resources is gearing up to take advantage.
Stellar Biotechnologies and Amaran Biotechnology have entered into an exclusive agreement where Stellar will supply KLH to the biopharmaceuticals manufacturer.
Several KLH-based vaccines are in trials for indications as varied as breast cancer and lupus, and clinical success could propel Stellar Biotechnologies, which is the only provider of KLH that has its own aquaculture facilities, says Jason McCarthy, an equity research analyst with Maxim Securities. Maxim currently has a price target of $4 on Stellar and the stock currently trades at around $1.65.
Irving Resources, Tightest Shares in Canada (03/01/2017)
Bob Moriarty of 321 Gold discusses Irving Resources, a spinoff from Gold Canyon Resources that has assets in northern Japan.
The Fantasy Continues (03/01/2017)
Rudi Fronk and Jim Anthony, co-founders of Seabridge Gold, assess President Donald Trump's speech to a joint session of Congress and find it wanting.
|"RP is finally in a position to drive substantial growth for shareholders by advancing all three clinical programs as well as continuing to build out their medical device."|
|"There's upside built into GRG, and I'd hate to miss out on it."|
|"GUY's Q1/17 production of 41 Koz was ahead of our estimated 34 Koz."|
|"DRRX's data indicate that NASH patients had 10-30% greater drug exposure as compared to MCS, and DUR-928 was well tolerated overall."|
|"Preliminary metallurgical work at GSV's Main Dark Star is positive."|